Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011)
Biogen (BIIB) posted Current Deferred Tax Assets of $8.1 million for Q4 2011, down 92.78% on a QoQ basis from $112.2 million in Q4 2010, and down 92.78% year-over-year from $112.2 million in Q4 2010.
Powered by 
Analysis
Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011) Analysis & Trends
Biogen has reported Current Deferred Tax Assets for 2 years, with the latest figure at $8.1 million in Q4 2011.
- On a quarterly basis, Current Deferred Tax Assets fell 92.78% year-over-year to $8.1 million in Q4 2011; TTM through Dec 2011 was $8.1 million, a 92.78% decrease from a year earlier, with the FY2011 full-year figure at $8.1 million, down 92.78% from the prior year.
- Current Deferred Tax Assets was $8.1 million for Q4 2011 at Biogen, down from $112.2 million in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $112.2 million in Q4 2010, with the low at $8.1 million in Q4 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn |